VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a proprietary two-part processing method that involves…

Source

Previous articleMindMed Enrolls First Participant in a Study of its Session Monitoring System
Next articlePsygen Receives Dealer’s Licence from Health Canada